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Abstract
Background: The role of environmental exposures in the pathogenesis of ankylosing spondylitis (AS) remains unclear.
In particular, two types of exposures have been suspected to play a role: mechanical stress and infections. The objective
of this case-control study was to determine if childhood infections are associated with later development of AS.
Methods: The cases with AS were identified through the Swedish national outpatient specialised-care register, based
on having been given at least one AS diagnosis in the register between 2001 and 2010. Five controls per case were
identified in the Swedish population register, matched at the time-point of the index case’s first spondyloarthritis
diagnosis on sex, birth year, and county. All cases/controls matched prior to the age of 17 years were excluded, as well
as all cases/controls given a diagnosis of reactive arthritis or juvenile arthritis at any time point, or any other diagnosis
of a rheumatic disease, psoriasis, iridocyclitis, or inflammatory bowel disease before the time-point of matching.
All events of hospitalisation with an infection before the age of 17 years were retrieved from the register, and
categorised according to the focus of the infection. Odds ratios (ORs) and confidence intervals (CIs) were determined
through conditional logistic regression analyses.
Results: Of the 2453 cases with AS and 10,257 controls, 17.4 % of the cases and 16.3 % of the controls had been
hospitalised with an infection before the age of 17 years (OR 1.08, 95 % CI 0.96–1.22).
Appendicitis (1.5 % cases; 2.5 % controls; OR 0.59, 95 % CI 0.41–0.83), respiratory tract infections (cases 11.2 %; controls
9.2 %; OR 1.24, 95 % CI 1.07–1.44) and, in particular, tonsillitis (cases 3.7 %; controls 2.8 %; OR 1.31, 95 % CI 1.03–1.67)
were associated with AS. There were no associations between AS and any other type of infection, and the point
estimates were similar in several sensitivity analyses.
Conclusions: Childhood appendicitis was associated with a decreased risk, whereas respiratory tract infections
were associated with an increased risk for later development of AS. These findings support a possible relationship
between childhood infections and later development of AS, although the study is limited to infections resulting
in inpatient care.
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Background
An understanding of the genetic basis for ankylosing
spondylitis (AS) is expanding rapidly. According to studies
in twins, genetic factors, including human leukocyte anti-
gen 27 (HLA-B27), are now thought to account for >90 %
of the risk for AS [1]. In contrast, the role of environmental
exposures in the aetiology of AS remains unclear. Whereas
studies on twins and extended families do suggest that
non-hereditary factors are likely to be involved in the
pathogenesis, studies indicating a temporal relationship
between environmental exposures and the development of
AS are rare [2–4]. The two most prevailing theories sug-
gest that onset of AS in genetically susceptible individuals
may be triggered by either infections or by mechanical
stress [5, 6], and sparse data also suggests an association
with smoking [7].
Reactive arthritis, another spondyloarthritis (SpA) disease,
is usually triggered by enteric or urogenital infections, but
other infections, such as respiratory tract infections, can
also trigger the disease onset [8–10]. Like AS, reactive
arthritis is also strongly associated with HLA-B27 [11],
suggesting a significant genetic overlap with AS. Simi-
larly, in inflammatory bowel disease (IBD), enteric in-
fections or alterations in gut flora have been implicated
in the disease pathogenesis [12]. For example, in ulcera-
tive colitis, a decreased risk for developing the disease,
associated with prior appendicitis, has been described
in several patient cohorts. IBD also shares a genetic
overlap with AS, and while only a minority of patients
with AS have a clinically overt IBD, the majority have been
found to have a subclinical gut inflammation [13, 14]. The
definitive role of this gut inflammation in SpA has not
been determined, but it appears to share inflammatory
pathways with the bone/joint inflammation [15]. Studies
have also indicated differences in the gut flora between
patients with AS and healthy controls, suggesting that gut
dysbiosis may be involved in the disease pathogenesis [16],
a finding further supported by SpA models in HLA-B27
transgenic rats, where animals reared in a germ-free en-
vironment fail to develop gut and joint inflammation
[17]. In psoriasis, also related to the SpA disease group,
tonsillitis, specifically with streptococci, is well known
to trigger the guttate form, but is also suspected to play
a role in exacerbations of plaque psoriasis [18].
In contrast to the growing data supporting a role for
infections in the pathogenesis of other SpA and SpA-
related diseases, no such relationship has been shown
for AS, and attempts to link specific pathogens to the
disease have either not been successful or not possible to
replicate [16, 19, 20]. In this study, we compared the fre-
quency of childhood infections at hospitalisation between
cases later diagnosed with AS and matched population
controls. Our hypothesis was that AS would be associated
with childhood infections, and considering the similarities
with reactive arthritis and inflammatory bowel disease, in
particular with enteric and urogenital infections.
Methods
Setting
This is a case-control study based on four national registers
in Sweden.
Data sources
The Patient Register was initiated in 1964 as a hospitali-
sation register, and was expanded in 2001 with an out-
patient register for specialised care [21]. The registers
are considered to have an overall high validity [21].
The Population Register contains demographic data
for all residents in Sweden [22].
The Prescribed Drug Register was started in July 2005,
and contains anatomical therapeutic chemical (ATC) codes
and administrative data on all prescribed drugs dispensed
in Sweden [23].
The Swedish Rheumatology Quality Register (SRQ) con-
tains information on anti-rheumatic treatment in Sweden.
The register coverage for patients treated with tumour
necrosis factor alpha inhibitors (TNFi) is 85–90 % [24].
Study population
The AS cases were defined as having been given ≥1 diag-
nosis (according to the International Classification of
Diseases (ICD)) of AS in the specialised care outpatient
register between 2001 and 2010, being born in Sweden
in 1964 or later, and having lived in Sweden at least up
to the age of 17 years. The high validity of the AS diag-
noses in the register has been described previously [25].
Five controls per case were retrieved from the popula-
tion register, matched on sex, birth year, and county of
birth, at the time of the index cases’ first registered diag-
nosis of SpA, and with the same requirement of having
lived in Sweden at least until the age of 17 years.
In order to minimise the risk for the cases and con-
trols already having an inflammatory disorder before the
age of 17 years, all cases receiving their first registered
diagnosis of SpA before the age of 17 years, as well as all
cases and controls given a diagnosis of juvenile arthritis
or reactive arthritis at any time, or a diagnosis of any
other rheumatic disease, IBD, psoriasis, or iridocyclitis
before the time-point of the match were excluded (for ICD
and ATC codes see Additional file 1).
Exposure data
For cases and controls, all ICD codes corresponding to
an infection given at the time of discharge from in-
patient care before the age of 17 years were identified.
The data were categorised according to the primary focus
of the infection and, as a supplement to enteric infections
and respiratory tract infections, data for appendectomy
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and tonsillectomy were also collected. Data were also
retrieved from the prescribed drugs register and the SRQ
regarding use of immunosuppressive drugs and antibiotics
in 2006–2011.
Statistics
Odds ratios (ORs) with 95 % confidence intervals (CIs)
were computed for the association between the different
infectious exposures and AS using simple conditional
logistic regression.
SAS 9.4 was used for aggregation of data and SPSS 21
for statistical analysis.
Sensitivity analyses and stratification
Three a priori defined sensitivity analyses were per-
formed. The first included only cases matched at an age
of >26 years. The purpose of this analysis was to further
separate the time period of exposure to the infections
from the time-point of receiving the first SpA diagnosis,
giving a minimum of a 10-year lag period between the
exposures and the outcome, as recorded in the register.
The second included only cases treated with metho-
trexate, sulphasalazine, and/or TNFi, with the intention
of probably selecting a more severe AS phenotype.
The third included only cases/controls matched in
2007–2011, excluding all cases and controls treated with
immunosuppressive or cytostatic drugs, as well as spe-
cific drugs for IBD, during the year prior to matching.
The purpose of this was to further eliminate possible
cases and controls with an inflammatory disorder before
the match. The limitation to cases matched after 2007
was due to the fact that the Prescribed Drug Register
was started in July 2005. Comparisons of the frequencies
of dispensed prescriptions of antibiotics in the year prior
to match between cases and controls were also per-
formed using Fisher’s exact test.
An additional, fourth, post-hoc sensitivity analysis
was also performed, excluding cases and controls with
a diagnosis of IBD between the time-point of match
and up until 2 years after the first AS diagnosis, the ra-
tionale for this being the previously described associ-
ation between appendicitis and a lower risk for ulcerative
colitis [26, 27].
Two stratified analyses were also performed; the first
stratified on median age at first SpA diagnosis, and the
second for median age at appendectomy and tonsillectomy.
For the latter analysis, the procedures of appendectomy
and tonsillectomy were chosen, rather than the codes for
the corresponding infections/inflammations, in order to
avoid cases and controls with multiple registered diagnoses
at different ages. For the few cases and controls with more
than one registered tonsillectomy procedure, the first was
used for the analysis.
Results
Cases and controls
We identified 2453 cases with AS (64 % men) and 10,257
controls (mean 4.3 controls per case). Demographics,
AS-related disease manifestations, and pharmacological
treatment are shown in Table 1.
Table 1 Demographics, ankylosing spondylitis (AS)-related inflammatory diseases, and pharmacological treatment in cases and controls
Demographics Cases (n = 2453) Controls (n = 10,257)
Men, n (%) 1569 (64) 6587 (64)
Year of birth, median (min–max) 1971 (1964–1992) 1971 (1964–1992)
Age at first SpA-diagnosis (years), mean, SD (min–max) 30, 6.2 (17–46) 30, 6.2 (17–46)
AS-related inflammatory diseasesa
Iridocyclitis, n (%) 453 (19) 45 (0)
Inflammatory bowel disease, n (%) 102 (4) 37 (0)
Psoriasis, n (%) 122 (5) 79 (1)
Pharmacological treatment in 2011b
NSAID, n (%) 1279 (52) 9 (0)
TNF inhibitor, n (%) 553 (23) NAc
Methotrexate, n (%) 169 (7) 0
Sulphasalazine, n (%) 263 (11) 1 (0)
aAS-related inflammatory diseases are given as cumulative incidence until 2 years after first AS diagnosis for the cases and their matched controls
bBased on prescriptions in the prescribed drugs register during 2011, apart from the tumour necrosis factor alpha (TNF) inhibitor infliximab for which data were
based on recorded treatment in the Swedish Rheumatology Quality Register (SRQ) during 2011
cTotal TNF inhibitor exposure was not possible to determine for controls since treatment with infliximab for nonrheumatic diseases cannot be detected through
either the prescribed drugs register or SRQ. The frequency of any subcutaneous TNF inhibitors for controls during 2011 was n = 2
NA Not available, NSAID nonsteroidal anti-inflammatory drug, SpA spondyloarthritis
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Analyses
Of the AS cases, 426 (17.4 %) had a registered diagnosis
of any infection at a time of hospitalisation before the
age of 17 years, with the values for the controls being
1668 (16.3 %) (OR 1.08, 95 % CI 0.96–1.22). Figure 1
presents the numbers of exposed cases and controls for
each category of infection, and the corresponding ORs.
Appendicitis (cases n = 37 (1.5 %) and controls n = 260
(2.5 %); OR 0.59, 95 % CI 0.41–0.83) and appendectomy
(cases n = 60 (2.4 %) and controls n = 336 (3.3 %); OR
0.73, 95 % CI 0.55–0.97) were significantly associated
with a decreased OR for AS. Respiratory tract infections
(cases n = 274 (11.2 %) and controls n = 941 (9.2 %); OR
1.24, 95 % CI 1.07–1.44) and, in particular, tonsillectomy
(cases n = 82 (3.3 %) and controls n = 244 (2.4 %); OR
1.38, 95 % CI 1.06–1.77) were associated with an increased
OR for AS. For enteric infections overall and urogenital
infections there were no associations.
For the group registered with both appendicitis and
appendectomy (cases n = 37 (1.5 %) and controls n = 254
(2.5 %)) the OR was 0.60 (95 % CI 0.42–0.85), while for
the group registered with only appendectomy but not
appendicitis (cases n = 23 (0.9 %) and controls n = 82
(0.8 %)) the OR was 1.16 (95 % CI 0.73–1.86). For the
group registered with both tonsillitis and tonsillectomy
(cases n = 74 (3.0 %) and controls n = 222 (2.2 %)), the
OR was 1.38 (95 % CI 1.04–1.78). For the respiratory
tract infections, excluding tonsillectomy or tonsillitis
(cases n = 179 (7.3 %) and controls n = 636 (6.2 %)), the
OR was 1.20 (95 % CI 1.00–1.43).
The point estimates were of a similar direction and
magnitude in all of the sensitivity analyses (Table 2). In
the sensitivity analysis only including cases matched
2007–2011 there was no statistically significant difference
in the proportions receiving prescriptions of antibiotics in
the year prior to matching between cases and controls.
In the analysis stratified by median age at first SpA
diagnosis (17–30 years versus 31–46 years) all point esti-
mates were in the same direction and of similar magni-
tude as in the primary analysis, apart from tonsillitis and
tonsillectomy which were stronger in the younger age-
groups (age 17–30 years at first SpA diagnosis: tonsillitis,
OR 1.15 (95 % CI 1.13–2.94), and tonsillectomy, OR
1.65 (95 % CI 1.21 to 2.26); age 31–46 years at first SpA
diagnosis: tonsillitis, OR 0.97 (95 % CI 0.62–1.51), and
tonsillectomy, OR 0.94 (95 % CI 0.59–1.51).
The median age for appendectomy was 12 years and
for tonsillectomy 9 years (all procedures at an age above
16 years are disregarded). In the analysis stratifying on
median age at appendectomy, a stronger association was
observed in the age group 0–12 years (OR 0.61, 95 %
CI 0.42–0.89) compared to age group 13–16 years (OR
0.95, 95 % CI 0.63–1.43). For tonsillectomy, the
association was similar in the stratified age groups
(age 0–9 years, OR 1.43 (95 % CI 1.01–2.02), and age
10–16 years, OR 1.35 (95 % CI 0.94–1.93).
Odds Ratio
Fig. 1 Associations between childhood infections and a later diagnosis of ankylosing spondylitis. Based on a total of 2453 AS cases and 10,257
matched controls where exposure data to infections are based on registered events of an infection in inpatient care before the age of 17 years.
1Including all infectious foci, but not the procedures appendectomy or tonsillectomy; 2including appendicitis; 3including tonsillitis; 4also including
adenoidectomy. CI confidence interval, OR odds ratio
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Table 2 Sensitivity analyses of the associations between childhood infections and a later diagnosis of ankylosing spondylitis
Including only cases matched at an age
of 27 years or older
Cases (n = 1757) Controls (n = 7305) OR 95 % CI
All infectionsa 258 (14.7) 964 (13.2) 1.13 0.97–1.32
Entericb 74 (4.2) 333 (4.6) 0.91 0.70–1.19
Appendicitis 30 (1.7) 169 (2.3) 0.72 0.49–1.07
Appendectomy 46 (2.6) 234 (3.2) 0.82 0.59–1.13
Respiratory tractc 159 (9.0) 529 (7.2) 1.27 1.05–1.54
Tonsillitis 49 (2.8) 169 (2.3) 1.16 0.83–1.61
Tonsillectomyd 43 (2.4) 151 (2.1) 1.12 0.79–1.59
Skin 15 (0.9) 66 (0.9) 0.93 0.53–1.64
Urogenital tract 6 (0.3) 24 (0.3) 1.02 0.41–2.50
Other 35 (2.0) 113 (1.5) 1.34 0.91–1.97
Including only cases treated with methotrexate,
sulphasalazine, and/or TNFi
Cases (n = 794) Controls (n = 3288) OR 95 % CI
All infectionsa 141 (17.8) 553 (16.8) 1.06 0.86–1.31
Entericb 40 (5.0) 185 (5.6) 0.87 0.61–1.25
Appendicitis 12 (1.5) 85 (2.6) 0.58 0.31–1.06
Appendectomy 20 (2.5) 116 (3.5) 0.71 0.44–1.16
Respiratory tractc 93 (11.7) 329 (10.0) 1.20 0.93–1.54
Tonsillitis 34 (4.3) 96 (2.9) 1.48 0.98–2.24
Tonsillectomyd 27 (3.4) 78 (2.4) 1.42 0.90–2.24
Skin 12 (1.5) 38 (1.2) 1.37 0.71–2.66
Urogenital tract 1 (0.1) 16 (0.5) 0.28 0.037–2.10
Other 14 (1.8) 59 (1.8) 0.991 0.54–1.81
Including only cases matched 2007–2011 and excluding
all with immunosuppressive or cytostatic treatment,
as well as specific treatment for inflammatory bowel disease,
1 year prior to match
Cases (n = 471) Controls (n = 1836) OR 95 % CI
All infectionsa 96 (20.4) 329 (17.9) 1.16 0.89–1.52
Entericb 26 (5.5) 102 (5.6) 0.92 0.59–1.45
Appendicitis 6 (1.3) 38 (2.1) 0.57 0.24–1.36
Appendectomy 11 (2.3) 48 (2.6) 0.84 0.43–1.63
Respiratory tractc 63 (13.4) 191 (10.4) 1.33 0.97–1.81
Tonsillitis 27 (5.7) 67 (3.6) 1.58 0.99–2.53
Tonsillectomyd 20 (4.2) 54 (2.9) 1.40 0.82–2.38
Skin 3 (0.6) 21 (1.1) 0.56 0.16–1.90
Urogenital tract 4 (0.8) 8 (0.4) 2.03 0.61–6.78
Other 14 (3.0) 45 (2.5) 1.29 0.70–2.40
Prescription of antibiotics 1 year prior to match 131 (27.8) 478 (26.0) p = 0.446
Excluding inflammatory bowel diseasee Cases (n = 2307) Controls (n = 9584) OR 95 % CI
All infectionsa 405 (17.6) 1555 (16.2) 1.10 0.97–1.25
Entericb 108 (4.7) 528 (5.5) 0.84 0.67–1.04
Appendicitis 35 (1.5) 244 (2.5) 0.59 0.41–0.84
Appendectomy 56 (2.4) 312 (3.3) 0.74 0.55–0.98
Respiratory tractc 258 (11.2) 873 (9.1) 1.25 1.08–1.46
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Discussion
Principal findings
In this study we found that appendicitis in childhood
was associated with a lower OR for AS, and that respira-
tory tract infections were associated with a weak increase
in the OR, which was more pronounced for tonsillitis.
Our initial hypothesis was that infections in general
during childhood, particularly in the enteric and uro-
genital tracts, would be associated with an increased
risk for later development of AS. However, our results
did not indicate any such association with either infec-
tions in general, or specifically with enteric or urogenital
tract infections.
Appendicitis has repeatedly been shown to have a pro-
tective association with ulcerative colitis, thought to be
linked somehow to the inflammation itself rather than
the appendectomy [26, 27]. In this study, the decreased
OR observed for appendicitis remained much the same
after exclusion of cases and controls with IBD, suggesting
that the effect was not conveyed through IBD comor-
bidity. The point estimates for appendicitis and ap-
pendectomy were also conserved throughout the other
sensitivity analyses, suggesting a robust effect. For re-
spiratory tract infections, the OR also attained statis-
tical significance; however, the magnitude of the effect
was in fact similar to that of enteric infections and uro-
genital tract infections. The reason that the latter two
did not meet statistical significance might be due to the
relatively low frequency of these infections, implying that
a larger number of cases and controls were needed for re-
spiratory tract infections to reach statistical difference.
This may suggest that the strength of the association
between respiratory tract infections overall and the risk of
developing AS is relatively weak. For tonsillitis and tonsil-
lectomy, the increase in risk for development of AS was
consistently stronger than for respiratory tract infections
overall in all sensitivity analyses except when only including
cases receiving a registered diagnosis of SpA after the age
of 26 years.
There are several remarks to make concerning the
possible biological interpretation of our findings. First,
it is not possible to draw any conclusions concerning
causality for the association found between different
types of infections and later development of AS. In-
deed, since the frequency for all types of infections was
relatively low among both the cases and the controls,
and the time span between the exposures and the out-
come was long, such an effect may be biologically im-
probable. Still, it cannot be ruled out that the different
infections during childhood could induce long-lasting
immunological effects that may affect the disease onset
in genetically predisposed individuals. If so, then it is
also possible that repeated infections in the same indi-
vidual may enforce such an effect, but the frequencies
of readmissions with the same infection were too low
to analyse in our study (data not shown). Second, we
know that HLA is central to the function of the adap-
tive immune system, and that different HLA types have
been shown to be associated with differences in the re-
sponse to different pathogens; for example, HLA-B27
has been shown to be related to a higher chance for
viral clearance in hepatitis C and a better prognosis in
HIV [28, 29]. It is possible that the immune phenotype
of AS, including HLA-B27, leading up to the develop-
ment of AS also conveys a hitherto unknown increase
in risk for respiratory tract infections and a decrease in
risk for appendicitis. For appendicitis, a genetic compo-
nent has been suggested but the inflammation is gener-
ally believed to be triggered by infections [30]. Third, it
is also possible that the similar decrease in risk for both
AS and ulcerative colitis, associated with appendicitis,
is related to the connection between gut inflammation
and AS. A fourth possibility is that appendicitis and
respiratory tract infections, or the treatment of such,
alters the gut flora, leading to a pathological imbalance
between microbes and immune phenotype, which in
turn affects the risk of developing AS [16]. In our
stratified analysis, the association with appendicitis was
stronger in the age group 0–12 years, which may sug-
gest that the possible biological or immunological im-
pact of the inflammation is of greater importance if
occurring early in life.
Table 2 Sensitivity analyses of the associations between childhood infections and a later diagnosis of ankylosing spondylitis (Continued)
Tonsillitis 87 (3.8) 257 (2.7) 1.37 1.07–1.77
Tonsillectomyd 78 (3.4) 219 (2.3) 1.42 1.09–1.85
Skin 23 (1.0) 102 (1.1) 0.94 0.59–1.49
Urogenital tract 9 (0.4) 40 (0.4) 0.90 0.44–1.86
Other 53 (2.3) 192 (2.0) 1.18 0.87–1.62
All values are shown as n (%)
Exposure data are based on registered events of an infection in inpatient care before the age of 17 years
aIncluding all infectious foci, but not the procedures appendectomy or tonsillectomy; bincluding appendicitis; cincluding tonsillitis; dalso including adenoidectomy;
eexcluding all cases/controls with a diagnosis of ulcerative colitis, Crohns’ disease, or any other non-infectious bowel inflammation (see Additional file 1) up until
2 years after the first AS diagnosis of the index case
CI confidence interval, OR odds ratio, TNFi tumour necrosis factor alfa inhibitors
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Limitations
First, there may be an issue of reverse causality since the
time point of disease onset for AS cannot be precisely
determined from the healthcare registers used. We per-
formed one sensitivity analysis in order to further sepa-
rate the time period for exposures to infections from
the time point of disease onset which resulted in similar
point estimates, supporting the temporal order of the
infections occurring prior to the AS onset. However,
this temporal separation of exposures and disease onset
also precludes the possibility of detecting any associ-
ation between infections and AS onset that are close in
time, as in the case of reactive arthritis. Second, we
only have reliable data for infections diagnosed in in-
patient care, reflecting more severe infections. This will
underestimate the frequency of infections (e.g. enteric,
respiratory, or urogenital) which are normally treated
in outpatient care or not treated at all, and it cannot be
assumed that the “tip of the iceberg” spectrum of infec-
tions that we detect are representative of all childhood
infections. By contrast, appendicitis is routinely treated
in inpatient care; hence, this result is unlikely to be
biased by any selection with regard to exposure.
Strengths
First, this is the first study directly investigating the rela-
tionship between infections during childhood and later
development of AS. Second, the high coverage of the na-
tional registers minimises selection bias, and our previous
validation study of the AS diagnoses in the register sup-
port the validity and generalisability of the results [21, 25].
Conclusions and implications
Appendicitis during childhood was associated with a de-
creased risk for adult AS, whereas respiratory tract infec-
tions were associated with an increased risk. Further
studies are required to determine if these associations are a
result of the immune phenotype leading to AS, or whether
the infections in fact alter the risk for AS. Such studies
would preferably take into account HLA-B27 status, but
also other risk genes and wider range of infectious expo-
sures, not limiting the latter to infections at hospitalisation.
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